Healthcare -
Medical - Healthcare Plans - NASDAQ - US
$ 3.055
-1.95 %
$ 1.55 B
Market Cap
-75.5
P/E
1. INTRINSIC VALUE
Balance Sheet
Clover Health Investments, Corp.
| Current Assets | 343 M |
| Cash & Short-Term Investments | 222 M |
| Receivables | 92.8 M |
| Other Current Assets | 28.8 M |
| Non-Current Assets | 238 M |
| Long-Term Investments | 202 M |
| PP&E | 5.31 M |
| Other Non-Current Assets | 30.6 M |
| Current Liabilities | 214 M |
| Accounts Payable | 34.6 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 179 M |
| Non-Current Liabilities | 26.1 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 26.1 M |
EFFICIENCY
Earnings Waterfall
Clover Health Investments, Corp.
| Revenue | 1.37 B |
| Cost Of Revenue | 1.01 B |
| Gross Profit | 365 M |
| Operating Expenses | 411 M |
| Operating Income | -45.7 M |
| Other Expenses | -2.74 M |
| Net Income | -43 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Clover Health Investments, Corp.
| Net Income | -43 M |
| Depreciation & Amortization | 1.33 M |
| Capital Expenditures | -1.56 M |
| Stock-Based Compensation | 114 M |
| Change in Working Capital | 12.9 M |
| Others | -28.6 M |
| Free Cash Flow | 33.3 M |
Wall Street Analysts Price Targets
Clover Health Investments, Corp.
Wall Street analysts predict an average 1-year price target for CLOV of $3.76 , with forecasts ranging from
a
low of
$1.8 to a high of $6 .
CLOV Lowest Price Target
Wall Street Target
1.8 USD
-41.08%
CLOV Average Price Target
Wall Street Target
3.76 USD
23.08%
CLOV Highest Price Target
Wall Street Target
6 USD
96.40%
4. DIVIDEND
ANALYSIS
CLOV does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Clover Health Investments, Corp.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.2 M USD 3
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
2 M USD 1
9-12 MONTHS
7. News
All You Need to Know About Clover Health Investments (CLOV) Rating Upgrade to Strong Buy
Clover Health Investments (CLOV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
zacks.com
- 1 month ago
Clover Health: Stars Are Aligning For GAAP Profitability In FY 2026
Clover reported impressive Q1 earnings with robust topline growth and improving profitability metrics thanks to a 30% YoY increase in its member base. Clover could see $95 million in additional revenues in FY 2026 without any member growth as a result of CMS increasing MA payouts by 5.1%. With Clover set to be eligible for a 5% quality bonus in 2026 thanks to its 4-star rating, I expect it to reach GAAP profitability in FY 2026.
seekingalpha.com
- 1 month ago
CLOV Stock Rises as Q1 Earnings Beat Estimates, Revenues Up Y/Y
Clover Health's first-quarter 2025 results continue to benefit from the strength of its strong member retention. A decline in operating loss bodes well.
zacks.com
- 1 month ago
Clover Health Investments, Corp. (CLOV) Q1 2025 Earnings Call Transcript
Clover Health Investments, Corp. (NASDAQ:CLOV ) Q1 2025 Earnings Conference Call May 6, 2025 5:00 PM ET Company Participants Ryan Schmidt - Investor Relations Andrew Toy - Chief Executive Officer Peter Kuipers - Chief Financial Officer Conference Call Participants Jonathan Yong - UBS Matt Hewitt - Craig-Hallum Capital Richard Close - Canaccord Genuity Operator Ladies and gentlemen, good afternoon and welcome to the Clover Health First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
seekingalpha.com
- 1 month ago
Clover Health Investments, Corp. (CLOV) Surpasses Q1 Earnings Estimates
Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of $0.05 per share a year ago.
zacks.com
- 1 month ago
Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance
First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-year First quarter 2025 Total revenues of $462 million, up 33% year-over-year Medicare Advantage medical costs are in line with expectations, underscoring the strength of Clover's technology-first care management model Meaningful improvement across first quarter 2025 profitability metrics: GAAP Net loss of $1 million, as compared to a GAAP Net loss of $19 million a year ago Adjusted EBITDA of $26 million, up 279% year-over-year Adjusted Net income of $25 million, up 322% year-over-year Improved Full Year 2025 Guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year at the midpoint Insurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpoint Adjusted EBITDA profitability between $50 million and $70 million Adjusted Net income between $50 million and $70 million WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today reported financial results for the first quarter 2025.
globenewswire.com
- 1 month ago
Watch These 3 MedTech Stocks for Q1 Earnings: Beat or Miss?
MedTech companies' quarterly results are likely to reflect strength in customer demand. Let's see how FMS, MASI and CLOV are placed ahead of their earnings releases.
zacks.com
- 1 month ago
Primary Care Physician Use of Counterpart Assistant Technology Associated with Better Health Outcomes in Patients with Congestive Heart Failure
New whitepaper highlights how a relationship with a Primary Care Physician (“PCP”) that uses Counterpart Assistant is associated with better clinical management, and fewer hospitalizations (18% lower) and readmissions (25% lower) in heart failure patients New whitepaper highlights how a relationship with a Primary Care Physician (“PCP”) that uses Counterpart Assistant is associated with better clinical management, and fewer hospitalizations (18% lower) and readmissions (25% lower) in heart failure patients
globenewswire.com
- 1 month ago
Clover Health Announces Changes to Board of Directors
Thomas L. Tran will become Chairman of the Audit Committee and the Nominating and Corporate Governance Committee, and Lee A. Shapiro will not stand for re-election at the 2025 Annual Shareholders' Meeting Thomas L. Tran will become Chairman of the Audit Committee and the Nominating and Corporate Governance Committee, and Lee A. Shapiro will not stand for re-election at the 2025 Annual Shareholders' Meeting
globenewswire.com
- 1 month ago
Clover Health to Participate in Upcoming Investor Conferences
WILMINGTON, Del., April 21, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced its participation in the following investor conferences:
globenewswire.com
- 1 month ago
Clover Health to Report First Quarter 2025 Financial Results on May 6, 2025
WILMINGTON, Del., April 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will report first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on May 6, 2025, to discuss Clover Health's first quarter 2025 business and financial results.
globenewswire.com
- 2 months ago
Clover Health Appoints Industry Veteran as Chief Medical Officer of Medicare Advantage
Dr. Shelly Gupta Brings Over a Decade of Medicare Advantage and Healthcare Leadership Experience Dr. Shelly Gupta Brings Over a Decade of Medicare Advantage and Healthcare Leadership Experience
globenewswire.com
- 2 months ago
8. Profile
Summary
Clover Health Investments, Corp. CLOV
COUNTRY
US
INDUSTRY
Medical - Healthcare Plans
MARKET CAP
$ 1.55 B
Dividend Yield
0.00%
Description
Clover Health Investments, Corp. operates as a medicare advantage insurer in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.
Contact
725 Cool Springs Blvd, Franklin, TN, 37067
https://www.cloverhealth.com
IPO
Date
June 12, 2020
Employees
570
Officers
Ms. Rachel Fish
Chief People Officer
Mr. Andrew Toy
Co-Founder, Chief Executive Officer & Director
Ms. Wendy Richey
Chief Compliance Officer
Dr. Kumar Dharmarajan
Chief Medical Officer of Clover Assistant
Ms. Karen Soares
General Counsel, Senior Vice President & Corporate Secretary
Ms. Jamie L. Reynoso
Chief Executive Officer of Medicare Advantage
Mr. Vivek Garipalli
Co-Founder & Executive Chairman
Mr. Peter J. Kuipers
Chief Financial Officer
Mr. Brady Priest J.D.
Chief Executive Officer of Home Care
Mr. Conrad Wai
Chief Executive Officer of Counterpart Health